Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?

Allergan’s $639m purchase of Vitae Pharmaceuticals gives the company an oral drug for a key dermatology indication and the potential to address other autoimmune disorders consistent with its focus on seven key therapeutic areas.